Pfizer hosts media conference in Kuwait
Kuwait, The Gulf Observer: Emphasizing the need to raise awareness about migraine, Pfizer hosted a media roundtable conference alongside leading healthcare professional Dr Jasem Al-Hashel to highlight the difference between a headache and a migraine, understand migraine causes and triggers and how to manage them, and recognize when to see a neurologist.
A common misconception about migraine can be deduced when having severe cases of headaches. A migraine is not just a bad headache. It is a debilitating neurological disease that leads to an intense headache which may be accompanied by other symptoms such as nausea, vomiting, visual problems, or increased sensitivity to light or sound.
Migraines might range in the period. Some typically last between four hours and three days, while other people experience migraines several times a week. Some might only experience attacks every few years. Patients who experience headaches for fifteen days or more every month, eight of these being migraines, suffer from chronic migraines.
Pfizer hosted a media roundtable conference to highlight the difference between a headache and a migraine
Although migraines are not life-threatening, they can negatively affect the quality of people’s physical and mental lives, as they interfere significantly with occupational, educational, familial, and social responsibilities. According to a study conducted by Global Burden of Disease, migraine is the second most prevalent disease in Kuwait, with a higher prevalence rate in females than males by 1.8 times.
Considering migraine causes, he indicated that migraine is also mostly affect doctors and medical students more than others because of tension, which is also triggered when exposed to psychological pressures due to life changes or certain events, changing sleep schedules, dehydration, where the patient must drink between 3-4 liters per day.
Regarding Pfizer’s oral treatment for migraine, Dr Nadine Tarcha, Gulf Medical Director, Pfizer, stated “This medication is an innovative dual-acting oral migraine treatment which is approved for the acute treatment of migraine in Kuwait. It brings us closer to our goal of helping patients suffering from this debilitating neurological disease, many of whom do not have satisfactory treatment options today.”
Dr Tarcha indicated that earlier in 2022, Pfizer announced the acquisition of Biohaven, and with this acquisition, Pfizer believes there is an opportunity to change the paradigm in migraine treatment and potentially establish a new standard of care, adding “In particular, it reinforces Pfizer Internal Medicine’s mission of bringing breakthroughs to the health challenges that affect millions of patients impacted by migraine.”
